Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Hepatitis C Virus AND Hepatitis C

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44349   clinical trials with a EudraCT protocol, of which   7376   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    959 result(s) found for: Hepatitis C Virus AND Hepatitis C. Displaying page 28 of 48.
    «« First « Previous 24  25  26  27  28  29  30  31  32  Next» Last»»
    EudraCT Number: 2006-005940-99 Sponsor Protocol Number: PERICO Start Date*: 2007-03-03
    Sponsor Name:vicente soriano
    Full Title: Open, multicentral and randomized study of phase IV to evaluate efficacy and safety to extent of treatment with Peginterferon alpha-2a (40 KD) combined with high doses of Ribavirin with support of ...
    Medical condition: hepatitis C in patients co infected with HIV
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-002585-12 Sponsor Protocol Number: A3L00057 Start Date*: 2020-08-03
    Sponsor Name:SANOFI PASTEUR
    Full Title: Immunogenicity and Safety of DTaP-IPV-HB-PRP~T Combined Vaccine Given at 3, 5, and 12 Monhs of Age Concomitantly or Sequentially 4CMenB Vaccine in Italian Infants
    Medical condition: Haemophilus influenzae type b immunisation
    Disease: Version SOC Term Classification Code Term Level
    21.1 10042613 - Surgical and medical procedures 10054181 Hepatitis B immunization LLT
    21.1 10042613 - Surgical and medical procedures 10069533 Haemophilus influenzae type b immunisation PT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: IT (Completed) FI (Completed)
    Trial results: View results
    EudraCT Number: 2007-005344-25 Sponsor Protocol Number: HCV 07-01 Start Date*: 2008-03-19
    Sponsor Name:Foundation for Liver Research
    Full Title: High-dose versus standard-dose weight-based ribavirin in combination with peginterferon alfa-2a for patients infected with hepatitis C virus genotype 1 or 4
    Medical condition: Chonic hepatitis C
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-000318-31 Sponsor Protocol Number: HepNed-001 Start Date*: 2016-03-09
    Sponsor Name:Erasmus MC
    Full Title: Ledipasvir and sofosbuvir for 8 weeks for the treatment of chronic hepatitis C genotype 4 in patients without cirrhosis. HepNed-001 study
    Medical condition: Hepatitis C
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-002468-20 Sponsor Protocol Number: AI443-102 Start Date*: 2013-12-13
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 3 Evaluation of a daclatasvir/asunaprevir/BMS-791325 Fixed Dose Combination in Non-cirrhotic Subjects with Genotype 1 Chronic Hepatitis C
    Medical condition: HEPATITIS C VIRUS
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004848 10072848 Hepatitis C virus genotype 1 positive LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2013-002458-66 Sponsor Protocol Number: AI443-113 Start Date*: 2013-12-13
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 3 Evaluation of a daclatasvir/asunaprevir/BMS-791325 Fixed Dose Combination in Subjects with Genotype 1 Chronic Hepatitis C and Compensated Cirrhosis
    Medical condition: HEPATITIS C VIRUS
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004848 10072848 Hepatitis C virus genotype 1 positive LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2015-003077-15 Sponsor Protocol Number: EIG-LNF-002 Start Date*: 2015-11-23
    Sponsor Name:Eiger BioPharmaceuticals
    Full Title: A Phase 2, Open-Label Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Activity of Titrating-Dose Lonafarnib in Combination with Ritonavir in Patients Chronically Infected w...
    Medical condition: Chronic Hepatitis D Virus (HDV) Infection.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-005929-49 Sponsor Protocol Number: VX11-787-101 Start Date*: 2012-02-20
    Sponsor Name:Vertex Pharmaceuticals Incorporated
    Full Title: A Phase 2a, Randomized, Double Blind, Placebo Controlled Study to Investigate the Effects of VX 787 Administered to Adult Volunteers Experimentally Inoculated with Live Influenza Virus
    Medical condition: Influenza A
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10022002 Influenza A virus infection LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-000725-37 Sponsor Protocol Number: GS-US-183-0149 Start Date*: 2015-02-18
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 1 Study to Evaluate the Bioavailability of Boosted Age-Appropriate Pediatric Elvitegravir (EVG) Tablet or Suspension Formulation Compared with Adult EVG 150 mg Tablets in Healthy Adult Volu...
    Medical condition: Human Immunodeficiency Virus (HIV-1) Infection
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004862 10020192 HIV-1 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2011-004272-11 Sponsor Protocol Number: 2B Start Date*: 2011-11-30
    Sponsor Name:Erasmus MC
    Full Title: The BOKITO-2B Study: Tenofovir DF Bone and Kidney Toxicity. Incidence and reversibility in HBV-monoinfected patients.
    Medical condition: Chronic hepatitis B
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-001325-14 Sponsor Protocol Number: 580299/008 Start Date*: 2004-08-12
    Sponsor Name:GlaxoSmithKline SA
    Full Title: Estudio en fase III, doble ciego, aleatorizado, controlado, multicéntrico para evaluar la eficacia de la vacuna HPV-16/18 VLP/AS04 de GlaxoSmithKline Biologicals comparada con la vacuna antihepatit...
    Medical condition: cervical cancer => study is conducted in healthy female
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2015-005191-18 Sponsor Protocol Number: HAF78 Start Date*: 2015-11-19
    Sponsor Name:Sanofi Pasteur SA
    Full Title: Immunogenicity and Safety of Sanofi Pasteur’s AVAXIM 80U Pediatric Vaccine Administered in Healthy Adolescents, Children and Toddlers in People’s Republic of China Followed by a Booster Dose 6 Mont...
    Medical condition: Hepatitis A
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2008-008190-58 Sponsor Protocol Number: TMC310911-TiDP21-C201 Start Date*: 2009-04-03
    Sponsor Name:Tibotec Pharmaceuticals
    Full Title: A Phase IIa, open-label, randomized trial in treatment-naïve HIV-1-infected subjects to determine the antiviral activity of 14 days of monotherapy with 4 different dose regimens of TMC310911 co-adm...
    Medical condition: HIV-1
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020192 HIV-1 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-005766-34 Sponsor Protocol Number: ABI-H0731-204 Start Date*: 2021-07-22
    Sponsor Name:Assembly Biosciences, Inc.
    Full Title: A Randomized Phase 2a, Multicenter, Open-Label, Multiple-Cohort Study Evaluating Regimens Containing Vebicorvir in Subjects with Chronic Hepatitis B Virus Infection
    Medical condition: Chronic Hepatitis B Virus Infection
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10008910 Chronic hepatitis B PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BG (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2004-001249-14 Sponsor Protocol Number: 102547 Start Date*: 2004-10-18
    Sponsor Name:GlaxoSmithKline
    Full Title: A Phase III open, multicentre, booster vaccination study to assess the immunogenicity, safety and reactogenicity of a booster dose of GlaxoSmithKline (GSK) Biologicals’ Haemophilus influenzae type ...
    Medical condition: Booster vaccination against Haemophilus influenzae type b and meningococcal serogroup C diseases.
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2018-004581-34 Sponsor Protocol Number: FIHP201801 Start Date*: 2019-04-02
    Sponsor Name:Fundación Instituto Hispalense de Pediatría
    Full Title: An open-label Phase IV trial to evaluate the immunogenicity and safety of Diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inactivated) and Haemophilus infl...
    Medical condition: Vaccines, Bacterial and viral vaccines combined
    Disease:
    Population Age: Preterm newborn infants, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-005591-33 Sponsor Protocol Number: HIVCOBOC-RGT Start Date*: 2013-07-29
    Sponsor Name:Universitätsklinik f. Innere Medizin III, Medizinische Universität Wien
    Full Title: Response-guided triple therapy using boceprevir in combination with PEGIFN/RBV in HIV/HCV coinfected patients
    Medical condition: Chronic genotype 1 HCV coinfection in HIV-positive patients.
    Disease: Version SOC Term Classification Code Term Level
    16.0 10021881 - Infections and infestations 10065949 HCV coinfection LLT
    16.0 10021881 - Infections and infestations 10020161 HIV infection PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2013-002821-41 Sponsor Protocol Number: 106793 Start Date*: 2014-01-21
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: Persistence of hepatitis B antibodies, immunogenicity and safety of GSK Biologicals’ hepatitis B vaccine EngerixTM-B Kinder (SKF103860) challenge dose in adolescents vaccinated with four doses of I...
    Medical condition: Hepatitis B
    Disease: Version SOC Term Classification Code Term Level
    17.0 10021881 - Infections and infestations 10021881 Infections and infestations SOC
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-018326-39 Sponsor Protocol Number: CB-2010-01 Start Date*: 2010-04-20
    Sponsor Name:Department of Genito-Urinary Medicine and Infectious Diseases
    Full Title: An open-label, randomised pilot study comparing the efficacy, safety and tolerability of raltegravir with protease inhibitor-based therapy in treatment-naïve, HIV/Hepatitis C co-infected injecting ...
    Medical condition: HIV-1/Hepatitis C co-infected patients
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10020161 HIV infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-002045-23 Sponsor Protocol Number: GS-US-180-0104 Start Date*: 2008-07-18
    Sponsor Name:Gilead Sciences Incorporated
    Full Title: A Double-blind, Randomized, Placebo-controlled Phase 1/2 Study of the Safety, Pharmacokinetics, and Antiviral Activity of GS-9131 in Antiretroviral-Naive, HIV-1 Infected Subjects.
    Medical condition: Antiretroviral treatment–naive subjects chronically infected with HIV-1
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020192 HIV-1 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 24  25  26  27  28  29  30  31  32  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Jul 18 07:35:18 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA